Barrat Franck J, Meeker Thea, Gregorio Josh, Chan Jean H, Uematsu Satoshi, Akira Shizuo, Chang Bonnie, Duramad Omar, Coffman Robert L
Dynavax Technologies Corporation, Berkeley, CA 94710, USA.
J Exp Med. 2005 Oct 17;202(8):1131-9. doi: 10.1084/jem.20050914.
Raised serum levels of interferon (IFN)-alpha have been observed in systemic lupus erythematosus (SLE) patients, and these levels are correlated with both disease activity and severity. The origin of this IFN-alpha is still unclear, but increasing evidence suggests the critical involvement of activated plasmacytoid predendritic cells (PDCs). In SLE patients, DNA and RNA viruses, as well as immune complexes (ICs), that consist of autoantibodies specific to self-DNA and RNA protein particles can stimulate production of IFN-alpha. We have developed three series of oligonucleotide (ODN)-based inhibitors of Toll-like receptor (TLR) signaling. These ODNs include inhibitors of TLR9, inhibitors of TLR7 but not TLR9, and sequences that inhibit both TLR7 and TLR9. Specificity of these inhibitors is confirmed by inhibition of IFN-alpha production by PDCs in response to DNA or RNA viruses. We show that mammalian DNA and RNA, in the form of ICs, are potent self-antigens for TLR9 and TLR7, respectively, and induce IFN-alpha production by PDCs. This work suggests that TLRs may have a critical role in the promotion of lupus through the induction of IFN-alpha by PDCs. These inhibitors of TLR signaling thus represent novel therapeutic agents with potential for the treatment of lupus.
系统性红斑狼疮(SLE)患者血清中干扰素(IFN)-α水平升高,且这些水平与疾病活动度和严重程度均相关。这种IFN-α的来源仍不清楚,但越来越多的证据表明活化的浆细胞样前树突状细胞(pDC)起着关键作用。在SLE患者中,DNA和RNA病毒以及由针对自身DNA和RNA蛋白颗粒的自身抗体组成的免疫复合物(IC)可刺激IFN-α的产生。我们开发了基于寡核苷酸(ODN)的三类Toll样受体(TLR)信号通路抑制剂。这些ODN包括TLR9抑制剂、TLR7而非TLR9的抑制剂以及同时抑制TLR7和TLR9的序列。这些抑制剂的特异性通过抑制pDC对DNA或RNA病毒产生IFN-α得以证实。我们发现,IC形式的哺乳动物DNA和RNA分别是TLR9和TLR7的有效自身抗原,并可诱导pDC产生IFN-α。这项研究表明,TLR可能通过pDC诱导IFN-α在狼疮的发病过程中起关键作用。因此,这些TLR信号通路抑制剂代表了具有治疗狼疮潜力的新型治疗药物。